|
|
|
|
Introduction
- Highly active antiretroviral therapy (HAART) based on two nucleoside analogue reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI) is a recommended initial regimen for the treatment of HIV-1 infection.1
PI exposure can be raised or �boosted� by co-administration of a second drug such as ritonavir. Due to favourable clinical data on PI/ritonavir combinations such as saquinavir/ritonavir, this approach is recommended in current guidelines for antiretroviral therapy1-3 and has also been successfully employed during the development of lopinavir/ritonavir.4,5
This section of the site aims to explain the principles and rationale behind PI boosting and highlights some of the ongoing investigations and approaches to the use of this strategy.
For some PIs, however, boosting is still largely investigational and the outcome of ongoing clinical trials are awaited to further assess the safety and effectiveness of these strategies. |
|
| « Back |
Next » |
|
|
